{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:07:26Z","timestamp":1778612846547,"version":"3.51.4"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1754","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the neonatal Fc receptor (FcRn) blocker nipocalimab (Imaavy \u2013 Janssen) for IV treatment of generalized myasthenia gravis (gMG) in patients \u226512 years old with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The FcRn blocker rozanolixizumab (Rystiggo) was approved earlier for the same indication.<\/jats:p>","DOI":"10.58347\/tml.2026.1754g","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:08:26Z","timestamp":1778609306000},"page":"e81-e83","source":"Crossref","is-referenced-by-count":0,"title":["Nipocalimab (Imaavy) for Myasthenia Gravis"],"prefix":"10.58347","volume":"68","member":"37151","published-online":{"date-parts":[[2026,5,11]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:08:26Z","timestamp":1778609306000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1754g"}},"subtitle":[],"editor":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":0,"journal-issue":{"issue":"1754","published-online":{"date-parts":[[2026,5,11]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2026.1754g","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}